Key Takeaways
- Tempus and Northwestern’s Abrams Center unite to tackle Alzheimer’s using AI-powered genomic insights.
- Tempus Lens platform to analyze large neurogenomic datasets, identifying novel targets and cell-level disease mechanisms.
- Goal: Catalyze new therapeutics and shorten development time for Alzheimer’s interventions with precision analytics.
Transforming Alzheimer’s Research with AI and Precision Genomics
In a multi-year collaboration announced today, Tempus AI (NASDAQ: TEM) and Northwestern University’s Abrams Research Center on Neurogenomics aim to redefine how Alzheimer’s disease is studied, diagnosed, and treated. Central to this effort is Tempus Lens, a cutting-edge AI platform capable of restructuring massive genomic datasets and uncovering hidden biological patterns. By applying AI directly to human neurogenomic data, the partnership seeks to illuminate gene functions, identify disease-driving cell types, and surface new therapeutic pathways.
Strategic Alliance Accelerates Data-to-Discovery for Neurodegenerative Diseases
Alzheimer’s disease, a condition notoriously resistant to effective treatment, has long suffered from limited biological insight. The Lens platform will integrate with Northwestern’s robust genomic repository to deliver high-resolution, actionable intelligence. By decoding how genomic variations influence disease progression, the collaboration sets the stage for data-backed hypotheses, faster biomarker identification, and the rational design of new clinical tools.
Bringing Precision Medicine to Neurology: A Mission-Aligned Approach
“This partnership is about turning complexity into clarity,” said Ryan Fukushima, COO of Tempus. “By combining Tempus’ AI capabilities with the Abrams Center’s neurogenomic expertise, we are targeting one of medicine’s most elusive conditions.” Dr. David Gate, who leads the Abrams Center, echoed the sentiment: “Our collaboration with Tempus helps realize our vision of precision neurology, where AI is used not just to interpret the genome—but to change the course of brain disease.”
Toward a New Era of AI-Augmented Neurotherapeutics
This initiative could serve as a blueprint for integrating AI-enabled platforms into neurological research at scale. With Alzheimer’s disease affecting over 6 million Americans—and with treatments still largely symptomatic—the promise of AI to detect patterns invisible to human researchers is seen as a critical inflection point. The collaboration may accelerate the discovery of next-generation therapeutics, with broad implications for neurodegenerative conditions beyond Alzheimer’s, including Parkinson’s, ALS, and frontotemporal dementia.
About Tempus
Tempus is a leading technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal clinical and molecular data, and a powerful operating system to make that data accessible and actionable, Tempus enables physicians to deliver personalized care and empowers researchers to accelerate the discovery and development of new therapeutics. Through its AI-driven platforms, Tempus is transforming patient outcomes across oncology, neurology, cardiology, and infectious diseases.
By
